Evidence map›Paper›PMID 38811642›Full record

ArticleScientific reports2024

Investigating surface proteins and antibody combinations for detecting circulating tumor cells of various sarcomas.

Minh-Chau N Le, Kierstin A Smith, Pablo J Dopico, Beate Greer, Morteza Alipanah, Yang Zhang, Dietmar W Siemann, Joanne P Lagmay, Z Hugh Fan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Minimal Residual Disease in Metastatic Soft Tissue Sarcoma.Current treatment options in oncology · 2025
    Review
  6. Review
  7. Review
  8. CIRCUS: CIRCUlating tumour cells in soft tissue Sarcoma - a short report.Cancer drug resistance (Alhambra, Calif.) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Minh-Chau N LeInterdisciplinary Microsystems Group, Department of Mechanical and Aerospace Engineering, University of Florida, PO Box 116250, Gainesville, FL, 32611, USA.
Kierstin A SmithInterdisciplinary Microsystems Group, Department of Mechanical and Aerospace Engineering, University of Florida, PO Box 116250, Gainesville, FL, 32611, USA.
Pablo J DopicoInterdisciplinary Microsystems Group, Department of Mechanical and Aerospace Engineering, University of Florida, PO Box 116250, Gainesville, FL, 32611, USA.
Beate GreerDepartment of Pediatrics, Division of Hematology-Oncology, University of Florida, Gainesville, FL, 32610, USA.
Morteza AlipanahInterdisciplinary Microsystems Group, Department of Mechanical and Aerospace Engineering, University of Florida, PO Box 116250, Gainesville, FL, 32611, USA.
Yang ZhangInterdisciplinary Microsystems Group, Department of Mechanical and Aerospace Engineering, University of Florida, PO Box 116250, Gainesville, FL, 32611, USA.
Dietmar W SiemannDepartment of Radiation Oncology, University of Florida, Gainesville, FL, 32610, USA.
Joanne P LagmayDepartment of Pediatrics, Division of Hematology-Oncology, University of Florida, Gainesville, FL, 32610, USA. jplagmay@ufl.edu.
Z Hugh FanInterdisciplinary Microsystems Group, Department of Mechanical and Aerospace Engineering, University of Florida, PO Box 116250, Gainesville, FL, 32611, USA. hfan@ufl.edu.

Funding

Team-based Interdisciplinary Cancer Research Training ProgramT32CA257923 · NCI · UNIVERSITY OF FLORIDA · PI SIEMANN, DIETMAR W · 2021 to 2025
$1.2M
Florida Department of Health 23L05National Science Foundation Graduate Research Fellowship Program DGE-1842473NCI NIH HHS T32 CA257923University of Florida Health Cancer Center Predoctoral Awards
6 · The paper itself

Abstract

Circulating tumor cells (CTCs) have gathered attention as a biomarker for carcinomas. However, CTCs in sarcomas have received little attention. In this work, we investigated cell surface proteins and antibody combinations for immunofluorescence detection of sarcoma CTCs. A microfluidic device that combines filtration and immunoaffinity using gangliosides 2 and cell surface vimentin (CSV) antibodies was employed to capture CTCs. For CTC detection, antibodies against cytokeratins 7 and 8 (CK), pan-cytokeratin (panCK), or a combination of panCK and CSV were used. Thirty-nine blood samples were collected from 21 patients of various sarcoma subtypes. In the independent samples study, samples were subjected to one of three antibody combination choices. Significant difference in CTC enumeration was found between CK and panCK + CSV, and between panCK and panCK + CSV. Upon stratification of CK

Indexed as

Biomarkers, TumorNeoplastic Cells, CirculatingSarcomaAdultAgedAntibodiesCell Line, TumorFemaleHumansKeratinsMaleMembrane ProteinsMiddle AgedVimentinAntibodiesBiomarkers, TumorKeratinsMembrane ProteinsVimentin

Identifiers

PMID38811642
PMCPMC11137101

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.